711 Development of oncolytic adenovirus Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) for the treatment of solid tumours – from preclinical testing to phase I clinical trials

• Tuomo Alanko,
• Akseli Hemminki,
• Víctor Cervera-Carrascón,
• Riikka Havunen,
• João Manuel Santos,
• Juha Kononen,
• Jorma Sormunen,
• Katriina Peltola,
• Riitta Korpisaari,
• Marjut Jaakkola,
• Suvi Sorsa,
• Santeri A Pakola,
• James Clubb,
• Elise Jirovec,
• Dafne CA Quixabeira,
• Tatiana Kudling,
• Lyna Haybout,
• Claudia Kistler

Affiliations

Tuomo Alanko

4Docrates Cancer Center, Helsinki, Finland

Akseli Hemminki

1TILT Biotherapeutics, Helsinki, Finland

Víctor Cervera-Carrascón

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Riikka Havunen

1TILT Biotherapeutics, Helsinki, Finland

João Manuel Santos

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Juha Kononen

4Docrates Cancer Center, Helsinki, Finland

Jorma Sormunen

4Docrates Cancer Center, Helsinki, Finland

Katriina Peltola

3Comprehensive Cancer Centre, Helsinki, Finland

Riitta Korpisaari

4Docrates Cancer Center, Helsinki, Finland

Marjut Jaakkola

4Docrates Cancer Center, Helsinki, Finland

Suvi Sorsa

1TILT Biotherapeutics, Helsinki, Finland

Santeri A Pakola

5University of Helsinki, Helsinki, Finland

James Clubb

1TILT Biotherapeutics, Helsinki, Finland

Elise Jirovec

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Dafne CA Quixabeira

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Tatiana Kudling

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Lyna Haybout

1TILT Biotherapeutics, Helsinki, Finland

Claudia Kistler

1TILT Biotherapeutics, Helsinki, Finland